Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial-Reference-Cited by-同舟云学术

Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial

Published:2018-10-07 Issue:2 Volume:21 Page:234-243
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Wang Weiqing¹,Nevárez Luis²,Filippova Ekaterina³,Song Ki Ho⁴,Tao Bei¹,Gu Liqun⁵,Wang Feng⁵,Li Pengfei⁵,Yang Jun⁵

Affiliation:

1. Rui Jin Hospital; Shanghai China

2. Hospital Angeles; Chihuahua Mexico

3. Medinet, LLC; St. Petersburg Russia

4. Yeouido St. Mary's Hospital; Seoul Republic of Korea

5. Lilly Suzhou Pharmaceutical Company Ltd; Shanghai China

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13506/fullpdf

Reference32 articles.

1. Pathogenesis of type 2 diabetes mellitus;DeFronzo;Med Clin North Am,2004

2. Standards of care for type 2 diabetes in China;Weng;Diabetes Metab Res Rev,2016

3. Standards of medical care in diabetes-2015: summary of revisions Diabetes Care 2015 38 suppl 1

4. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long);Zinman;Diabetes Care,2012

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Injectable Dulaglutide 1.5 mg Among Type 2 Diabetes Patients in Clinics at King Saud Medical City, Riyadh, Saudi Arabia;Journal of Epidemiology and Global Health;2024-05-16

2. A randomized, double‐blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes (AWARD‐JPN);Diabetes, Obesity and Metabolism;2024-05-07

3. Comparing Efficacy and Safety of Glucagon-Like Peptide 1 (GLP-1) Agonist Versus Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Chinese Patients with Type 2 Diabetes Mellitus: A Preliminary Study;International Journal of Pharmacology;2024-05-01

4. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians;Annals of Internal Medicine;2024-05

5. Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials;Diabetes, Obesity and Metabolism;2023-11-29